Chemotherapy-induced peripheral neuropathy: A current review

Nathan P Staff, Anna Grisold, Wolfgang Grisold, Anthony J Windebank, Nathan P Staff, Anna Grisold, Wolfgang Grisold, Anthony J Windebank

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting side effect experienced by patients receiving treatment for cancer. Approximately 30 to 40% of patients treated with neurotoxic chemotherapy will develop CIPN, and there is considerable variability in its severity between patients. It is often sensory-predominant with pain and can lead to long-term morbidity in survivors. The prevalence and burden of CIPN late effects will likely increase as cancer survival rates continue to improve. In this review, we discuss the approach to peripheral neuropathy in patients with cancer and address the clinical phenotypes and pathomechanisms of specific neurotoxic chemotherapeutic agents. Ann Neurol 2017;81:772-781.

Conflict of interest statement

POTENTIAL CONFLICTS OF INTEREST

None

© 2017 American Neurological Association.

Figures

Figure 1
Figure 1
Neurotoxic chemotherapeutic agents target multiple aspects of the sensory peripheral nerve.

References

    1. Pike CT, Birnbaum HG, Muehlenbein CE, Pohl GM, Natale RB. Healthcare costs and workloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer. Chemother Res Pract. 2012;2012:913848.
    1. Brugnoletti F, Morris EB, Laningham FH, et al. Recurrent intrathecal methotrexate induced neurotoxicity in an adolescent with acute lymphoblastic leukemia: Serial clinical and radiologic findings. Pediatr Blood Cancer. 2009 Feb;52(2):293–5.
    1. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. The Lancet Oncology. 2011 May;12(5):431–40.
    1. Briani C, Vitaliani R, Grisold W, et al. Spectrum of paraneoplastic disease associated with lymphoma. Neurology. 2011 Feb 22;76(8):705–10.
    1. Stubgen JP. Lymphoma-associated dysimmune polyneuropathies. J Neurol Sci. 2015 Aug 15;355(1-2):25–36.
    1. Baehring JM, Batchelor TT. Diagnosis and management of neurolymphomatosis. Cancer journal (Sudbury, Mass. 2012 Sep-Oct;18(5):463–8.
    1. Grisariu S, Avni B, Batchelor TT, et al. Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report. Blood. 2010 Jun 17;115(24):5005–11.
    1. Grisold WGA, Marosi Ch, Meng S, Briani Ch. Neuropathies associated with lymphoma. Neuro-Oncology Practice. 2015;2(4):167–178. 2015.
    1. Viala K1BA, Maisonobe T, Léger JM. Neuropathy in lymphoma: a relationship between the pattern of neuropathy, type of lymphoma and prognosis? J Neurol Neurosurg Psychiatry. 2008 Jul;79(7):778–82. Epub 2007 Oct 30.
    1. Baehring JM, Damek D, Martin EC, Betensky RA, Hochberg FH. Neurolymphomatosis. Neuro Oncol. 2003 Apr;5(2):104–15.
    1. Tomita MKH, Kawagashira Y, et al. Clinicopathological features of neuropathy associated with lymphoma. Brain. 2013;136(Pt 8):2563–2578. 2013.
    1. Bayat EKJ. Neurological complications in plasma cell dyscrasias. Handb Clin Neurol. 2012;105:731–46. 2012.
    1. Kelly JJ1KD. Lymphoma and peripheral neuropathy: a clinical review. Muscle Nerve. 2005 Mar;31(3):301–13. 2005.
    1. Amato AA, Barohn RJ, Sahenk Z, Tutschka PJ, Mendell JR. Polyneuropathy complicating bone marrow and solid organ transplantation. Neurology. 1993 Aug;43(8):1513–8.
    1. Krouwer HG, Wijdicks EF. Neurologic complications of bone marrow transplantation. Neurol Clin. 2003 Feb;21(1):319–52.
    1. Mathew RM, Rosenfeld MR. Neurologic Complications of Bone Marrow and Stem-cell Transplantation in Patients with Cancer. Current treatment options in neurology. 2007 Jul;9(4):308–14.
    1. Rodriguez TE. Neurologic complications of bone marrow transplantation. Handb Clin Neurol. 2014;121:1295–304.
    1. Gertz MA. Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment. American journal of hematology. 2014 Dec;89(12):1132–40.
    1. Shin SC, Robinson-Papp J. Amyloid neuropathies. The Mount Sinai journal of medicine, New York. 2012 Nov-Dec;79(6):733–48.
    1. Common Terminology Criteria for Adverse Events (CTCAE) v4.0. 2016 Available from: .
    1. Pachman DR, Qin R, Seisler DK, et al. Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance) J Clin Oncol. 2015 Oct 20;33(30):3416–22.
    1. Binda D, Vanhoutte EK, Cavaletti G, et al. Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS) Eur J Cancer. 2013 Sep;49(13):2910–8.
    1. Cavaletti G, Jann S, Pace A, et al. Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst. 2006 Jun;11(2):135–41.
    1. Binda D, Cavaletti G, Cornblath DR, Merkies IS, group CI-Ps Rasch-Transformed Total Neuropathy Score clinical version (RT-TNSc((c)) ) in patients with chemotherapy-induced peripheral neuropathy. J Peripher Nerv Syst. 2015 Sep;20(3):328–32.
    1. Frisina RD, Wheeler HE, Fossa SD, et al. Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Aug 10;34(23):2712–20.
    1. Krarup-Hansen A, Rietz B, Krarup C, Heydorn K, Rorth M, Schmalbruch H. Histology and platinum content of sensory ganglia and sural nerves in patients treated with cisplatin and carboplatin: an autopsy study. Neuropathol Appl Neurobiol. 1999 Feb;25(1):29–40.
    1. Johnson C, Pankratz VS, Velazquez AI, et al. Candidate pathway-based genetic association study of platinum and platinum-taxane related toxicity in a cohort of primary lung cancer patients. J Neurol Sci. 2015 Feb 15;349(1-2):124–8.
    1. Bentzen AG, Balteskard L, Wanderas EH, et al. Impaired health-related quality of life after chemoradiotherapy for anal cancer: late effects in a national cohort of 128 survivors. Acta Oncol. 2013 May;52(4):736–44.
    1. Schmoll HJ, Harstrick A, Bokemeyer C, et al. Single-agent carboplatinum for advanced seminoma. A phase II study. Cancer. 1993 Jul 1;72(1):237–43.
    1. Vandenput I, Vergote I, Neven P, Amant F. Weekly paclitaxel-carboplatin regimen in patients with primary advanced or recurrent endometrial carcinoma. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2012 May;22(4):617–22.
    1. Pignata S, Scambia G, Ferrandina G, et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J Clin Oncol. 2011 Sep 20;29(27):3628–35.
    1. Shahriari-Ahmadi A, Fahimi A, Payandeh M, Sadeghi M. Prevalence of Oxaliplatin-induced Chronic Neuropathy and Influencing Factors in Patients with Colorectal Cancer in Iran. Asian Pacific journal of cancer prevention : APJCP. 2015;16(17):7603–6.
    1. Gill JS, Windebank AJ. Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle. J Clin Invest. 1998 Jun 15;101(12):2842–50.
    1. McDonald ES, Windebank AJ. Cisplatin-induced apoptosis of DRG neurons involves bax redistribution and cytochrome c release but not fas receptor signaling. Neurobiol Dis. 2002 Mar;9(2):220–33.
    1. Podratz JL, Knight AM, Ta LE, et al. Cisplatin induced Mitochondrial DNA damage in dorsal root ganglion neurons. Neurobiol Dis. 2011 Mar;41(3):661–8.
    1. Park SB, Lin CS, Krishnan AV, Goldstein D, Friedlander ML, Kiernan MC. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain. 2009 Oct;132(Pt 10):2712–23.
    1. Sittl R, Lampert A, Huth T, et al. Anticancer drug oxaliplatin induces acute cooling-aggravated neuropathy via sodium channel subtype Na(V)1.6-resurgent and persistent current. Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6704–9.
    1. Pachman DR, Qin R, Seisler DK, et al. Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III trial N08CB (Alliance) Journal of Clinical Oncology. 2015;33(30):3416–22.
    1. Di Lorenzo G, Bracarda S, Gasparro D, et al. Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer. Medicine (Baltimore) 2016 Jan;95(2):e2299.
    1. Omlin A, Sartor O, Rothermundt C, et al. Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel. Clinical genitourinary cancer. 2015 Aug;13(4):e205–8.
    1. Loprinzi CL, Reeves BN, Dakhil SR, et al. Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Apr 10;29(11):1472–8.
    1. Reeves BN, Dakhil SR, Sloan JA, et al. Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1. Cancer. 2012 Oct 15;118(20):5171–8.
    1. Komiya Y, Tashiro T. Effects of taxol on slow and fast axonal transport. Cell Motil Cytoskeleton. 1988;11(3):151–6.
    1. Xiao WH, Zheng H, Bennett GJ. Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel. Neuroscience. 2012 Feb 17;203:194–206.
    1. Zheng H, Xiao WH, Bennett GJ. Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy. Exp Neurol. 2012 Dec;238(2):225–34.
    1. Lisse TS, Middleton LJ, Pellegrini AD, et al. Paclitaxel-induced epithelial damage and ectopic MMP-13 expression promotes neurotoxicity in zebrafish. Proc Natl Acad Sci U S A. 2016 Apr 12;113(15):E2189–98.
    1. Bokemeyer C, Berger CC, Kuczyk MA, Schmoll HJ. Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol. 1996 Nov;14(11):2923–32.
    1. Jain P, Gulati S, Seth R, Bakhshi S, Toteja GS, Pandey RM. Vincristine-induced neuropathy in childhood ALL (acute lymphoblastic leukemia) survivors: prevalence and electrophysiological characteristics. J Child Neurol. 2014 Jul;29(7):932–7.
    1. Lavoie Smith EM, Li L, Chiang C, et al. Patterns and severity of vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia. J Peripher Nerv Syst. 2015 Mar;20(1):37–46.
    1. Ramchandren S, Leonard M, Mody RJ, et al. Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia. J Peripher Nerv Syst. 2009 Sep;14(3):184–9.
    1. Atas E, Korkmazer N, Artik HA, Babacan O, Kesik V. Raynaud's phenomenon in a child with medulloblastoma as a late effect of chemotherapy. Journal of cancer research and therapeutics. 2015 Jul-Sep;11(3):666.
    1. Rosenthal S, Kaufman S. Vincristine neurotoxicity. Ann Intern Med. 1974 Jun;80(6):733–7.
    1. Chan SY, Worth R, Ochs S. Block of axoplasmic transport in vitro by vinca alkaloids. J Neurobiol. 1980 May;11(3):251–64.
    1. Geisler S, Doan RA, Strickland A, Huang X, Milbrandt J, DiAntonio A. Prevention of vincristine-induced peripheral neuropathy by genetic deletion of SARM1 in mice. Brain. 2016 Dec;139(Pt 12):3092–108.
    1. Carlson K, Ocean AJ. Peripheral neuropathy with microtubule-targeting agents: occurrence and management approach. Clinical breast cancer. 2011 Apr;11(2):73–81.
    1. Gopal AK, Ramchandren R, O'Connor OA, et al. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood. 2012 Jul 19;120(3):560–8.
    1. Krop IE, Modi S, LoRusso PM, et al. Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer. Breast Cancer Res. 2016 Mar 15;18(1):34.
    1. Chaudhry V, Cornblath DR, Polydefkis M, Ferguson A, Borrello I. Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy. J Peripher Nerv Syst. 2008 Dec;13(4):275–82.
    1. Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006 Jul 1;24(19):3113–20.
    1. Mauermann ML, Blumenreich MS, Dispenzieri A, Staff NP. A case of peripheral nerve microvasculitis associated with multiple myeloma and bortezomib treatment. Muscle Nerve. 2012 Dec;46(6):970–7.
    1. Ravaglia S, Corso A, Piccolo G, et al. Immune-mediated neuropathies in myeloma patients treated with bortezomib. Clin Neurophysiol. 2008 Nov;119(11):2507–12.
    1. Saifee TA, Elliott KJ, Rabin N, et al. Bortezomib-induced inflammatory neuropathy. J Peripher Nerv Syst. 2010 Dec;15(4):366–8.
    1. Kumar SK, Berdeja JG, Niesvizky R, et al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Lancet Oncol. 2014 Dec;15(13):1503–12.
    1. Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015 Jan 08;372(2):142–52.
    1. Meregalli C, Chiorazzi A, Carozzi VA, et al. Evaluation of tubulin polymerization and chronic inhibition of proteasome as citotoxicity mechanisms in bortezomib-induced peripheral neuropathy. Cell Cycle. 2014;13(4):612–21.
    1. Staff NP, Podratz JL, Grassner L, et al. Bortezomib alters microtubule polymerization and axonal transport in rat dorsal root ganglion neurons. Neurotoxicology. 2013 Dec;39:124–31.
    1. Casafont I, Berciano MT, Lafarga M. Bortezomib induces the formation of nuclear poly(A) RNA granules enriched in Sam68 and PABPN1 in sensory ganglia neurons. Neurotox Res. 2010 Feb;17(2):167–78.
    1. Palanca A, Casafont I, Berciano MT, Lafarga M. Proteasome inhibition induces DNA damage and reorganizes nuclear architecture and protein synthesis machinery in sensory ganglion neurons. Cell Mol Life Sci. 2014 May;71(10):1961–75.
    1. Grover JK, Uppal G, Raina V. The adverse effects of thalidomide in relapsed and refractory patients of multiple myeloma. Ann Oncol. 2002 Oct;13(10):1636–40.
    1. Morawska M, Grzasko N, Kostyra M, Wojciechowicz J, Hus M. Therapy-related peripheral neuropathy in multiple myeloma patients. Hematol Oncol. 2015 Dec;33(4):113–9.
    1. Fullerton PM, O'Sullivan DJ. Thalidomide neuropathy: a clinical electrophysiological, and histological follow-up study. J Neurol Neurosurg Psychiatry. 1968 Dec;31(6):543–51.
    1. Briani C, Torre CD, Campagnolo M, et al. Lenalidomide in patients with chemotherapy-induced polyneuropathy and relapsed or refractory multiple myeloma: results from a single-centre prospective study. J Peripher Nerv Syst. 2013 Mar;18(1):19–24.
    1. San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013 Oct;14(11):1055–66.
    1. Kirchmair R, Tietz AB, Panagiotou E, et al. Therapeutic angiogenesis inhibits or rescues chemotherapy-induced peripheral neuropathy: taxol- and thalidomide-induced injury of vasa nervorum is ameliorated by VEGF. Mol Ther. 2007 Jan;15(1):69–75.
    1. Kirchmair R, Walter DH, Ii M, et al. Antiangiogenesis mediates cisplatin-induced peripheral neuropathy: attenuation or reversal by local vascular endothelial growth factor gene therapy without augmenting tumor growth. Circulation. 2005 May 24;111(20):2662–70.
    1. Voskens CJ, Goldinger SM, Loquai C, et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One. 2013;8(1):e53745.
    1. Zimmer L, Goldinger SM, Hofmann L, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer. 2016 Apr 12;
    1. de Maleissye MF, Nicolas G, Saiag P. Pembrolizumab-Induced Demyelinating Polyradiculoneuropathy. N Engl J Med. 2016 Jul 21;375(3):296–7.
    1. Aya F, Ruiz-Esquide V, Viladot M, et al. Vasculitic neuropathy induced by pembrolizumab. Ann Oncol. 2016 Nov 17;
    1. Nokia MS, Anderson ML, Shors TJ. Chemotherapy disrupts learning, neurogenesis and theta activity in the adult brain. Eur J Neurosci. 2012 Dec;36(11):3521–30.
    1. Holmes D. Trying to unravel the mysteries of chemobrain. Lancet Neurol. 2013 Jun;12(6):533–4.
    1. Albers JW, Chaudhry V, Cavaletti G, Donehower RC. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev. 2014;3:CD005228.
    1. Majithia N, Temkin SM, Ruddy KJ, Beutler AS, Hershman DL, Loprinzi CL. National Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials: outcomes and lessons. Support Care Cancer. 2016 Mar;24(3):1439–47.
    1. Chaudhry V, Chaudhry M, Crawford TO, Simmons-O'Brien E, Griffin JW. Toxic neuropathy in patients with pre-existing neuropathy. Neurology. 2003 Jan 28;60(2):337–40.
    1. Chauvenet AR, Shashi V, Selsky C, Morgan E, Kurtzberg J, Bell B. Vincristine-induced neuropathy as the initial presentation of charcot-marie-tooth disease in acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Pediatr Hematol Oncol. 2003 Apr;25(4):316–20.
    1. Martino MA, Miller E, Grendys EC., Jr The administration of chemotherapy in a patient with Charcot-Marie-Tooth and ovarian cancer. Gynecol Oncol. 2005 May;97(2):710–2.
    1. Nakamura T, Hashiguchi A, Suzuki S, Uozumi K, Tokunaga S, Takashima H. Vincristine exacerbates asymptomatic Charcot-Marie-tooth disease with a novel EGR2 mutation. Neurogenetics. 2012 Feb;13(1):77–82.
    1. Abraham JE, Guo Q, Dorling L, et al. Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel. Clin Cancer Res. 2014 May 1;20(9):2466–75.
    1. Apellaniz-Ruiz M, Lee MY, Sanchez-Barroso L, et al. Whole-exome sequencing reveals defective CYP3A4 variants predictive of paclitaxel dose-limiting neuropathy. Clin Cancer Res. 2015 Jan 15;21(2):322–8.
    1. Azoulay D, Leibovici A, Sharoni R, et al. Association between Met-BDNF allele and vulnerability to paclitaxel-induced peripheral neuropathy. Breast Cancer Res Treat. 2015 Oct;153(3):703–4.
    1. Baldwin RM, Owzar K, Zembutsu H, et al. A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Sep 15;18(18):5099–109.
    1. Beutler AS, Kulkarni AA, Kanwar R, et al. Sequencing of Charcot-Marie-Tooth disease genes in a toxic polyneuropathy. Ann Neurol. 2014 Nov;76(5):727–37.
    1. Boora GK, Kulkarni AA, Kanwar R, et al. Association of the Charcot-Marie-Tooth disease gene ARHGEF10 with paclitaxel induced peripheral neuropathy in NCCTG N08CA (Alliance) J Neurol Sci. 2015 Oct 15;357(1-2):35–40.
    1. Chhibber A, Mefford J, Stahl EA, et al. Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance) Pharmacogenomics J. 2014 Aug;14(4):336–42.
    1. Leandro-Garcia LJ, Inglada-Perez L, Pita G, et al. Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy. J Med Genet. 2013 Sep;50(9):599–605.
    1. Leandro-Garcia LJ, Leskela S, Jara C, et al. Regulatory polymorphisms in beta-tubulin IIa are associated with paclitaxel-induced peripheral neuropathy. Clin Cancer Res. 2012 Aug 15;18(16):4441–8.
    1. Schneider BP, Li L, Radovich M, et al. Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199. Clin Cancer Res. 2015 Nov 15;21(22):5082–91.
    1. Wheeler HE, Gamazon ER, Wing C, et al. Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy. Clin Cancer Res. 2013 Jan 15;19(2):491–9.
    1. Broyl A, Corthals SL, Jongen JL, et al. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol. 2010 Nov;11(11):1057–65.
    1. Diouf B, Crews KR, Lew G, et al. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. Jama. 2015 Feb 24;313(8):815–23.
    1. Johnson DC, Corthals SL, Walker BA, et al. Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Mar 1;29(7):797–804.
    1. Argyriou AA, Cavaletti G, Antonacopoulou A, et al. Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study. Cancer. 2013 Oct 1;119(19):3570–7.
    1. Chen J, Yin J, Li X, et al. WISP1 polymorphisms contribute to platinum-based chemotherapy toxicity in lung cancer patients. Int J Mol Sci. 2014;15(11):21011–27.
    1. Custodio A, Moreno-Rubio J, Aparicio J, et al. Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: a GEMCAD group study. Ann Oncol. 2014 Feb;25(2):398–403.
    1. Lecomte T, Landi B, Beaune P, Laurent-Puig P, Loriot MA. Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 May 15;12(10):3050–6.
    1. McWhinney-Glass S, Winham SJ, Hertz DL, et al. Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity. Clin Cancer Res. 2013 Oct 15;19(20):5769–76.
    1. Bergmann TK, Vach W, Feddersen S, et al. GWAS-based association between RWDD3 and TECTA variants and paclitaxel induced neuropathy could not be confirmed in Scandinavian ovarian cancer patients. Acta Oncol. 2013 May;52(4):871–4.
    1. Chen EI, Crew KD, Trivedi M, et al. Identifying Predictors of Taxane-Induced Peripheral Neuropathy Using Mass Spectrometry-Based Proteomics Technology. PLoS One. 2015;10(12):e0145816.
    1. Gutierrez-Camino A, Martin-Guerrero I, Lopez-Lopez E, et al. Lack of association of the CEP72 rs924607 TT genotype with vincristine-related peripheral neuropathy during the early phase of pediatric acute lymphoblastic leukemia treatment in a Spanish population. Pharmacogenet Genomics. 2015 Nov 25;
    1. Peng Z, Wang Q, Gao J, et al. Association between GSTP1 Ile105Val polymorphism and oxaliplatin-induced neuropathy: a systematic review and meta-analysis. Cancer Chemother Pharmacol. 2013 Aug;72(2):305–14.
    1. Chambers SM, Qi Y, Mica Y, et al. Combined small-molecule inhibition accelerates developmental timing and converts human pluripotent stem cells into nociceptors. Nat Biotechnol. 2012 Jul;30(7):715–20.
    1. Avior Y, Sagi I, Benvenisty N. Pluripotent stem cells in disease modelling and drug discovery. Nat Rev Mol Cell Biol. 2016 Mar;17(3):170–82.
    1. Smith EM, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. Jama. 2013 Apr 3;309(13):1359–67.
    1. Majithia N, Smith TJ, Coyne PJ, et al. Scrambler Therapy for the management of chronic pain. Support Care Cancer. 2016 Jun;24(6):2807–14.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe